News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Talus Bioscience, a drug discovery company developing new treatments for cancer, inflammation, and other diseases, has announced $4.3 million in non-dilutive grant funding across three new awards.
Throughout 2023, the life sciences industry has been faced with many operational issues, including supply-chain uncertainty, inflation, and talent shortages.
Novartis’ board of directors has unanimously agreed to separate Sandoz as a 100 per cent spin-off with a $15 billion share buyback.